1
|
Redig A and McAllister S: Breast cancer as
a systemic disease: a view of metastasis. J of Intern Med.
274:113–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Brown JM: Tumor hypoxia in cancer therapy.
Methods Enzymol. 435:297–321. 2007.PubMed/NCBI
|
3
|
Ryan HE, Poloni M, McNulty W, et al:
Hypoxia-inducible factor-1alpha is a positive factor in solid tumor
growth. Cancer Res. 60:4010–4015. 2000.PubMed/NCBI
|
4
|
Vaupel P: The role of hypoxia-induced
factors in tumor progression. Oncologist. 9(Suppl 5): 10–17. 2004.
View Article : Google Scholar
|
5
|
Czekay RP, Aertgeerts K, Curriden SA and
Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from
extracellular matrices by inactivating integrins. J Cell Biol.
160:781–791. 2003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Giordano FJ and Johnson RS: Angiogenesis:
the role of the microenvironment in flipping the switch. Curr Opin
Genet Dev. 11:35–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
7
|
Maxwell PH, Pugh CW and Ratcliffe PJ:
Activation of the HIF pathway in cancer. Curr Opin Genet Dev.
11:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
|
8
|
Semenza GL: Hypoxia-inducible factor 1:
control of oxygen homeostasis in health and disease. Pediatr Res.
49:614–617. 2001. View Article : Google Scholar : PubMed/NCBI
|
9
|
Harada H: How can we overcome tumor
hypoxia in radiation therapy? J Radiat Res. 52:545–556. 2011.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Luo Y, Lan L, Jiang YG, et al:
Epithelial-mesenchymal transition and migration of prostate cancer
stem cells is driven by cancer-associated fibroblasts in an
HIF-1α/β-catenin-dependent pathway. Mol Cells. 36:138–144.
2013.PubMed/NCBI
|
11
|
Shang Q, Xu H and Huang L: Tanshinone IIA:
A promising natural cardioprotective agent. Evid Based Complement
Alternat Med. 2012:7164592012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wang WQ, Liu L, Sun HC, et al: Tanshinone
IIA inhibits metastasis after palliative resection of
hepatocellular carcinoma and prolongs survival in part via vascular
normalization. J Hematol Oncol. 5:692012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chen Z, Zhang D, Yue F, Zheng M, Kovacevic
Z and Richardson DR: The iron chelators Dp44mT and DFO inhibit
TGF-β-induced epithelial-mesenchymal transition via up-regulation
of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem.
287:17016–17028. 2012.PubMed/NCBI
|
14
|
Yang MH, Wu MZ, Chiou SH, et al: Direct
regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell
Biol. 10:295–305. 2008. View
Article : Google Scholar : PubMed/NCBI
|
15
|
Liu JJ, Lin DJ, Liu PQ, Huang M, Li XD and
Huang RW: Induction of apoptosis and inhibition of cell adhesive
and invasive effects by tanshinone IIA in acute promyelocytic
leukemia cells in vitro. J Biomed Sci. 13:813–823. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL
and Pang CY: Tanshinone IIA inhibits human prostate cancer cells
growth by induction of endoplasmic reticulum stress in vitro and in
vivo. Prostate Cancer Prostatic Dis. 16:315–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Su CC, Chen GW and Lin JG: Growth
inhibition and apoptosis induction by tanshinone I in human colon
cancer Colo 205 cells. Int J Mol Med. 22:613–618. 2008.PubMed/NCBI
|
18
|
Huang CY, Chiu TL, Kuo SJ, Chien SY, Chen
DR and Su CC: Tanshinone IIA inhibits the growth of pancreatic
cancer BxPC-3 cells by decreasing protein expression of TCTP, MCL-1
and Bcl-xL. Mol Med Rep. 7:1045–1049. 2013.PubMed/NCBI
|
19
|
Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF
and Zhang J: Growth inhibition and apoptosis induction of
tanshinone II-A on human hepatocellular carcinoma cells. World J
Gastroenterol. 10:2024–2028. 2004.PubMed/NCBI
|
20
|
Xu M, Cao FL, Li NY, Liu YQ, Li YP and Lv
CL: Tanshinone IIA reverses the malignant phenotype of SGC7901
gastric cancer cells. Asian Pac J Cancer Prev. 14:173–177. 2013.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Pan TL, Hung YC, Wang PW, et al:
Functional proteomic and structural insights into molecular targets
related to the growth inhibitory effect of tanshinone IIA on HeLa
cells. Proteomics. 10:914–929. 2010.PubMed/NCBI
|
22
|
Lin C, Wang L, Wang H, Yang L, Guo H and
Wang X: Tanshinone IIA inhibits breast cancer stem cells growth in
vitro and in vivo through attenuation of IL-6/STAT3/NF-κB signaling
pathways. J Cell Biochem. 114:2061–2070. 2013.PubMed/NCBI
|
23
|
Won SH, Lee HJ, Jeong SJ, Lü J and Kim SH:
Activation of p53 signaling and inhibition of androgen receptor
mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer
cells. Phytother Res. 26:669–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Cheng CY and Su CC: Tanshinone IIA may
inhibit the growth of small cell lung cancer H146 cells by
up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial
membrane potential. Mol Med Rep. 3:645–650. 2010.PubMed/NCBI
|
25
|
Yun SM, Jeong SJ, Kim JH, et al:
Activation of c-Jun N-terminal kinase mediates tanshinone
IIA-induced apoptosis in KBM-5 chronic myeloid leukemia cells. Biol
Pharm Bull. 36:208–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Xu M, Cao F, Liu L, et al: Tanshinone
IIA-induced attenuation of lung injury in endotoxemic mice is
associated with reduction of hypoxia-inducible factor 1α
expression. Am J Respir Cell Mol Biol. 45:1028–1035.
2011.PubMed/NCBI
|
27
|
Nguyen L, Fifis T, Malcontenti-Wilson C,
et al: Spatial morphological and molecular differences within solid
tumors may contribute to the failure of vascular disruptive agent
treatments. BMC Cancer. 12:5222012. View Article : Google Scholar
|
28
|
Hu Y, Wang S, Wu X, et al: Chinese herbal
medicine-derived compounds for cancer therapy: a focus on
hepatocellular carcinoma. J Ethnopharmacol. 149:601–612. 2013.
View Article : Google Scholar : PubMed/NCBI
|